Skip to main content
Get the Weekly ESG Brief

Edwards Lifesciences Corporation

EWNYSETrackedMarket Data VerifiedHealth CareHealth Care Equipment

Coverage
Coverage universe Identity published; no third-party ESG observation yet.
ESG profile reviewed
Last editorial update to this profile.
Quote
Last verified closeObservation time is shown beside the price.
Methodology
How we rateProvider ratings are shown separately, never blended.

Market overview

USD 88.08

Up+USD 1.25 (+1.44%) Day change

Last verified close · As of · USD · Market data via Massive Stock Widgets

The market is closed. This is the last verified closing quote, not an intraday price.

Open
USD 85.70
Previous close
USD 86.83
Day high
USD 88.19
Day low
USD 86.12
Volume
3,230,188
Market cap
USD 50,769,313,792
Price chart · 1 Year
Edwards Lifesciences Corporation 1 Year price chartEdwards Lifesciences Corporation, nyse:EW, 1 Year price chart in USD. Start USD 77.77, end USD 88.08, high USD 95.18, low USD 72.65, up.
Period1 YearFirst closeUSD 77.77Last closeUSD 88.08Maximum closeUSD 95.18Minimum closeUSD 72.65Period change+USD 10.31Period percentage change+13.26%Chart as ofSep 29, 2026, 1:30 PM GMT+0000
View Chart Data
Representative chart points — 24 of 251
Date and time Open High Low Close Volume
USD 77.14 USD 78.15 USD 76.78 USD 77.77 3,783,900
USD 73.01 USD 73.79 USD 72.42 USD 72.65 2,634,800
USD 86.29 USD 86.68 USD 84.74 USD 86.30 3,269,800
USD 86.60 USD 86.93 USD 85.18 USD 85.27 2,644,500
USD 83.16 USD 85.76 USD 82.31 USD 85.32 5,949,900
USD 85.46 USD 85.48 USD 84.08 USD 85.33 2,377,000
USD 83.73 USD 85.16 USD 82.82 USD 83.46 4,000,700
USD 81.48 USD 81.98 USD 79.62 USD 79.77 6,461,700
USD 78.60 USD 79.93 USD 78.00 USD 79.78 4,736,000
USD 80.87 USD 84.29 USD 80.54 USD 84.26 4,758,700
USD 81.65 USD 82.33 USD 80.60 USD 81.69 3,899,900
USD 82.02 USD 82.77 USD 81.36 USD 81.71 4,664,000
USD 81.53 USD 82.00 USD 79.19 USD 79.72 6,234,300
USD 82.89 USD 83.04 USD 79.24 USD 79.96 4,031,200
USD 86.25 USD 87.93 USD 85.52 USD 87.54 5,116,100
USD 86.59 USD 87.22 USD 85.10 USD 85.98 4,537,900
USD 90.31 USD 92.46 USD 89.33 USD 90.78 14,420,800
USD 94.36 USD 95.57 USD 92.72 USD 95.18 3,958,000
USD 90.48 USD 90.63 USD 88.20 USD 90.09 5,249,200
USD 84.79 USD 86.00 USD 82.91 USD 85.76 5,594,700
USD 91.66 USD 93.38 USD 91.66 USD 93.05 2,340,300
USD 90.78 USD 91.48 USD 89.79 USD 89.95 3,058,200
USD 85.45 USD 86.26 USD 85.12 USD 85.52 2,988,100
USD 85.70 USD 88.19 USD 85.70 USD 88.08 3,383,100

Company Profile & Business Model Overview

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient’s physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Sustainability Strengths & Catalysts (Pros)

  • Life-saving medical devices create inherent positive social impact aligned with UN SDGs while targeting 2.5M underserved patients
  • Clear carbon neutrality commitment by 2030 with science-based targets and multiple LEED Gold/Platinum certified facilities
  • Strong financial performance with 8.6% revenue growth and minimal debt supporting continued innovation and ESG investments

Material Risks & Governance Concerns (Cons)

  • Limited ESG transparency with undisclosed MSCI rating and minimal detailed reporting compared to industry peers
  • Medical device manufacturing inherently involves plastic waste challenges despite sustainability efforts

Related ESG Peer Equities

Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.

Explore Health Care Peers →

ESG & Sustainability Rating Breakdown

Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.

Audited Methodology

Coverage PendingThird-Party ESG Coverage Under Review

Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.

Data integrity and methodology

MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.

FAQ

Frequently Asked Questions

Direct answers on sustainability scores, risk methodologies, and peer rankings.

What is Edwards Lifesciences Corporation (EW)'s ESG rating and sustainability score?

Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Edwards Lifesciences Corporation (EW). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.

Is Edwards Lifesciences Corporation considered an ESG leader or laggard in Health Care?

Independent benchmark status for Edwards Lifesciences Corporation is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.

What are the main ESG risks and controversies for Edwards Lifesciences Corporation?

Key material risks for Edwards Lifesciences Corporation include: Limited ESG transparency with undisclosed MSCI rating and minimal detailed reporting compared to industry peers; Medical device manufacturing inherently involves plastic waste challenges despite sustainability efforts. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.

How does The Impact Investor evaluate ESG stock profiles?

The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.